Pancreatic triacylglycerol lipase (PL), α-amylase and α-glucosidase are interesting pharmacological targets for the management of dyslipidemia, atherosclerosis, and obesity-diabetes. Limonium spp (Plumbaginaceae) are endemic to Sardinia, Italy. Comparable with acarbose, aqueous extracts (AE) of L. contortirameum and L. virgatum, and their phytoconstituent gallic acid concentration gradients (mg/mL) were identified as in vitro potent (p<0.001, n=3) and efficacious dual inhibitors of α-amylase and α-glucosidase with respective IC 50 (mg/mL) values of 0.6 ± 0.1, 1.2 ± 0.1 and 0.15 ± 0.02. Equivalent to orlistat (PL IC 50 of 0.114 ± 0.004 µg/mL), L. contortirameum, L. virgatum AE and their phytoprinciple gallic acid inhibited PL substantially (p<0.001, n=3) in a dose-dependent manner in vitro with PL-IC 50 (µg/mL) of 920.4 ± 105.2, 593.1 ± 56.8 and 8.4 ± 0.9, respectively. LC-MS analysis of extracts revealed the presence of several phenolic compounds in their aglycon and glycoside forms. These are catechins, flavones, epigallocatechins and flavonols. Flavonoid-and polyphenol-rich L contortirameum and L. virgatum, modulating gastrointestinal carbohydrate and lipid digestion and absorption, may be advocated as candidates for obesity-diabetes prevention and phytotherapy.
Type 2 diabetes mellitus (DM) is characterized by multiple defects in insulin action and/or secretion. Most importantly, obesity expedites the risk for developing diabetes, or a combination of cardiovascular disorders known as metabolic syndrome [1a] . There is a persistent unmet need for medicinal plants and phytopharmaceuticals with scientifically proven antidiabetic efficacy and safety comparable with conventional medicine [1b,c] . Due to the good acceptance of herbal drugs among people, phytopharmaceuticals with demonstrated clinical efficacy could become a suitable alternative/complementary therapy to conventional medication. Similarly, possible antiobesity therapeutics from natural sources are being investigated as obesity reaches alarming epidemic proportions globally [1d,2]. Specifically, the accelerating and rising prevalence of obesity and diabetes in Italy-Sardinia has now become rather worrisome [3] [4] [5] [6] . The biological efficacies and pharmacological therapeutic benefits and phytochemical analyses of diverse Limonium spp. (Plumbaginaceae), native medicinal species of Sardinia-Italy, have been investigated [7, 8] . Among the natural antiobesity components, flavonoids, saponins, sitosterols, tritepenoids and tannins could provide marked antiobesity benefits by various mechanisms of action [9] [10] [11] . Numerous investigations were conducted to explore medicinal plants as potential therapeutic agents for dual management of diabetes and hyperlipidemia via inhibition of such digestive enzymes as pancreatic alpha-amylase, intestinal alphaglucosidase and pancreatic triacylglycerol lipase [12a,b] . Hence, the aim of the present study was to identify the major constituents of L. contortirameum and L. virgatum and to investigate the inhibitory effects of their crude aqueous extracts on the extrapancreatic digestive enzymes in vitro. LC-MS was used to characterize flavonoids. Results obtained through mass analysis in negative ion mode are given in Table 1 [12c]. The data show that both species contain large amounts of catechins such as catechin-3-gallate and epigallocatechin gallate; chalcons phloretin and phlorizin, and glycosides of myricetin and quercetin. Several studies have shown that myricetin could potentially be an anticarcinogen, as well as an antiviral and antimicrobial agent [12b, 13, 14] . Myricetin may have therapeutic potential, particularly in the treatment of non-insulin-dependent DM because it does not require a functional insulin receptor to exert its effect, does not mediate its effects by translocation of glucose transporters, and is able to enhance the stimulatory effects of insulin on glucose uptake [15a] . Quercetin, shows many beneficial health effects; it reduces blood glucose levels and improves plasma insulin levels in streptozotocin-induced diabetic rats, and is a candidate for preventing obesity-related diseases [15b,16a] . The chalcon phloretin and its glycoside phlorizin, also called phloridzin (phloretin-2-ß-Dglucose) act as competitive inhibitors of sodium/glucose cotransporters in the intestine (SGLT1) and kidney ( (Table 2) [17a] . Comparable with orlistat performance, a concentration dependent PL inhibition trend was observed for each of the tested extracts and their bioactive phytoconstituent gallic acid (the same Figure) . PL IC 50 values obtained for a minimum of triple separate determinations are also illustrated ( Table 2) . Catechins with the galloyl moiety were proved for in vitro inhibition of PL, thus suppressing effectively postprandial hypertriacylglycerolemia [17b,18a]. Importantly, gallic acid was found inhibitory to PL in vitro, and hence, has substantial antiobesity effects in vivo [18b]. In addition, myricetin was significantly associated with lipasenullifying efficacies of polyphenolic-rich fractions from native Australian herbs [18c]. Besides, quinic acid polyphenols, purified from coffee, could substantially suppress postprandial hyperlipidemia via dose-dependent inhibitory modulation of PL [19] . These significant antilipase effects may be strongly related to the potential synergies for inhibition by a number of bioactive principles present in Limonium spp. [20a] . Future acute and chronic in vivo testing against high fat diet obesity/hyperlipidemia may further ascertain these in vitro findings [20b]. Furthermore, Figure 3 demonstrates that corn starch incubations with all AEs (0.1-10 mg/ mL) of L. virgatum had highly significant dose-dependent (p<0.001) inhibition on glucose liberation with an IC 50 of 1.2 ± 0.1 mg/mL. More importantly, it is evident that 10 mg/mL AE of L. virgatum inhibited polysaccharide breakdown by almost 90% ( Table 3 ). The bioactive phyto-principle gallic acid showed highly significant (p<0.001 vs. control, n=3) concentration related dual inhibition of α-amylase and α-glucosidase in vitro culinary corn starch digestion with and IC 50 of 0.15 ±0.02 mg/mL (Figure 4 , Table 3 ).
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Preparation of the aqueous extracts (AEs):
AEs were prepared by refluxing 10 g of each dried, coarsely ground plant material with 100 mL tap water for 15 min. The extracts were stored overnight and then filtered twice through filter paper and the volume of the filtered solution was adjusted to 100 mL with tap water to obtain 10% (equivalent to 100 mg/1mL) crude aqueous solutions [21c]. Sonication of stock crude extract or testing concentrations was performed before implementation of investigations. For PL experimentation, water was evaporated under vacuum at 40 o C using a rotary evaporator. The solid residues were collected and stored in dry conditions until analysis.
LC system: An Agilent Technologies (Palo Alto, CA, USA) 1100 series LC/MSD equipped with a diode-array detector and an autosampler (G1313A) was used for LC separation. A ChemStation HP A.10.02 was used for data analysis. Chromatographic separation was achieved using a Luna C18 column (150 mm × 2.0 mm, 3µm, 90 A°) (Phenomenex, Torrance, CA, USA) fitted with a 3 µm Luna C18 security guard cartridge (4 mm × 2 mm). The column temperature was maintained at 37°C. The mobile phase consisted of Eluent A (water containing 0.01% acetic acid and 0.01% TFA) and Eluent B (acetonitrile). The separation was performed under gradient conditions with a flow rate of 0.4 mL/min and a run time of 55 min, and was followed by cleanup and equilibration (Table 4 ). . Gallic acid (dissolved in absolute ethanol) was prepared in 5 different stock solutions with a concentration range of 195 -6250 µg/ mL. Thereafter, a 20 μL aliquot of each stock solution was used in the reaction mixture to give a final concentration range of 3.9063 -125 µg/ mL. Orlistat, the reference drug (dissolved in DMSO; 1 mg/mL), was prepared in 6 different stock solutions with a concentration range of 0.625 -20 µg/ mL. Thereafter, 20 μL aliquot of each stock solution was used in the reaction mixture to give a final concentration range of 0.0125 -0.4 μg/ mL [17a] .
Spectrophotometric quantification of PL activity and assaying PL inhibition by test extracts and compounds:
In vitro enzymatic PL activity was assayed according to Bustanji et al.
[21e]. Subsequent determinations were undertaken for the tested extracts of gallic acid and orlistat in comparison with control evaluations, to calculate the concentration required for PL 50% inhibition (IC 50 )
In vitro enzymatic starch digestion assay: In vitro enzymatic starch digestion was assayed with acarbose, as the reference drug [22] . The extent of polysaccharide breakdown into glucose was evaluated in a concentration range of different plant aqueous extract 0.1, 0.5, 1.0, 1.25, 2.5, 5.0 and 10.0 mg/ mL. Gallic acid concentrations 6.25, 12.5, 25, 50, 100 and 200 µg/mL were tested for potential effects on enzymatic starch digestion, Control (tap water only) samples contained neither acarbose nor plant extract. 
Statistical analysis:

